Inhibikase Therapeutics (IKT) Times Interest Earned (2020 - 2022)
Inhibikase Therapeutics (IKT) reported Times Interest Earned of -$928119.2 for Q1 2022, down 416962.55% year-over-year from N/an in Q1 2021, and down 2808.74% quarter-over-quarter from -$31908.0 in Q4 2021.
Inhibikase Therapeutics (IKT) Times Interest Earned (2020 - 2022) Analysis & Trends
Inhibikase Therapeutics (IKT) has 3 years of Times Interest Earned data on file, last reported at -$928119.2 in Q1 2022.
- Times Interest Earned for Q1 2022 came in at -$928119.2, down 416962.55% year-over-year; the trailing twelve-month figure through Dec 2022 was -$3.6 million (down 489095.22% YoY), and the FY2021 annual result was -$741.16, down 673.17% from the prior year.
- Times Interest Earned retreated to -$928119.2 in Q1 2022 per IKT's latest filing, from -$31908.0 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$52.08 in Q2 2020 and troughed at -$928119.2 in Q1 2022.
- A 3-year average of -$109939.3 and a median of -$222.54 in 2021 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2021 and 2022: Times Interest Earned slumped 205.98% in 2021, then tumbled 416962.55% in 2022.
- A 3-year view of Times Interest Earned shows it stood at -$168.21 in 2020, then tumbled by 18869.2% to -$31908.0 in 2021, then sank by 2808.74% to -$928119.2 in 2022.
- Business Quant data shows IKT's Times Interest Earned at -$928119.2 in Q1 2022, -$31908.0 in Q4 2021, and -$28478.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -258.33 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 11.79 |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -928,119.20 |
| Dec 31, 2021 | -31,907.98 |
| Sep 30, 2021 | -28,477.96 |
| Jun 30, 2021 | -336.50 |
| Mar 31, 2021 | -222.54 |
| Dec 31, 2020 | -168.21 |
| Sep 30, 2020 | -96.33 |
| Jun 30, 2020 | -52.08 |
| Mar 31, 2020 | -72.73 |